What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Blood pressure
His scientific interests lie mostly in Internal medicine, Surgery, Blood pressure, Diabetes mellitus and Type 2 diabetes.
His Internal medicine research integrates issues from Placebo and Cardiology.
His Surgery research includes elements of Atorvastatin, Cohort study and Risk factor.
His studies deal with areas such as Hemodynamics, Epidemiology and Pediatrics as well as Blood pressure.
His work is dedicated to discovering how Diabetes mellitus, Disease are connected with Cognition and other disciplines.
His Type 2 diabetes research is multidisciplinary, relying on both Hypoglycemia, Nephropathy, Proportional hazards model, Diabetic angiopathy and Hazard ratio.
His most cited work include:
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (5527 citations)
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial (3235 citations)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (3062 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Blood pressure, Cardiology, Diabetes mellitus and Type 2 diabetes.
His Internal medicine research incorporates themes from Placebo, Endocrinology and Surgery.
His research investigates the connection between Blood pressure and topics such as Risk factor that intersect with issues in Physical therapy and Epidemiology.
His Cardiology research is multidisciplinary, incorporating perspectives in Amlodipine, Left ventricular hypertrophy, Atenolol and Heart rate.
His Diabetes mellitus research is multidisciplinary, incorporating elements of Proportional hazards model and Vascular disease.
Type 2 diabetes is closely attributed to Hazard ratio in his work.
He most often published in these fields:
- Internal medicine (53.17%)
- Blood pressure (36.76%)
- Cardiology (23.63%)
What were the highlights of his more recent work (between 2017-2021)?
- Blood pressure (36.76%)
- Internal medicine (53.17%)
- Diabetes mellitus (19.91%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Blood pressure, Internal medicine, Diabetes mellitus, Emergency medicine and Type 2 diabetes.
His Blood pressure study integrates concerns from other disciplines, such as Overweight, Risk factor and Environmental health.
He interconnects Liraglutide and Cardiology in the investigation of issues within Internal medicine.
His Liraglutide study combines topics in areas such as Placebo and Insulin.
In his work, Creatinine is strongly intertwined with Renal function, which is a subfield of Diabetes mellitus.
His Type 2 diabetes research includes themes of Vascular disease and Kidney disease.
Between 2017 and 2021, his most popular works were:
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials (81 citations)
- Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions (40 citations)
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. (38 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Blood pressure
- Disease
Internal medicine, Blood pressure, Diabetes mellitus, Hazard ratio and Placebo are his primary areas of study.
His biological study spans a wide range of topics, including Liraglutide, Type 2 diabetes, Type 2 Diabetes Mellitus and Cardiology.
His work carried out in the field of Type 2 diabetes brings together such families of science as Proportional hazards model and Insulin.
His work in the fields of Blood pressure, such as Elevated blood, intersects with other areas such as Statistical analysis.
He usually deals with Diabetes mellitus and limits it to topics linked to Renal function and Perindopril, Creatinine, Angiotensin-converting enzyme, Renin–angiotensin system and Gastroenterology.
The concepts of his Hazard ratio study are interwoven with issues in Albuminuria and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
